SCHEMBL30186325

SCHEMBL30186325

CCCCOC(=O)N1C2CC(F)CC1CC(Oc1ccc(Cl)nn1)C2

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ GPR119 Q8TDV5 2/20 0.33
▸ ALDH1A1 P00352 1/20 0.31
▸ KMT2A Q03164 1/20 0.31
▸ CYP1A2 P05177 1/20 0.31
▸ CYP2D6 P10635 1/20 0.31
▸ CYP2C9 P11712 1/20 0.31
▸ TSHR P16473 1/20 0.31
▸ CYP2C19 P33261 1/20 0.31
▸ ECE1 P42892 1/20 0.31
▸ BCHE P06276 1/20 0.31
▸ KDM4E B2RXH2 1/20 0.31
▸ MAPK1 P28482 1/20 0.31
▸ L3MBTL1 Q9Y468 1/20 0.31
▸ KCNK3 O14649 1/20 0.31
▸ KCNK9 Q9NPC2 1/20 0.31
▸ POLB P06746 1/20 0.31
▸ HTR3E A5X5Y0 1/20 0.31
▸ HTR3B O95264 1/20 0.31
▸ HTR3A P46098 1/20 0.31
▸ HTR3D Q70Z44 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28650955 0.81 GPR119 (0.41) GPR119KMT2AKCNK3KCNK9
SCHEMBL28650954 0.81 GPR119 (0.41) GPR119KMT2AKCNK3KCNK9
SCHEMBL22325318 0.81 KCNH2 (0.34) KMT2ASMN1; SMN2
SCHEMBL25394185 0.76 SMN1; SMN2 (0.43) ALDH1A1CYP1A2CYP2D6CYP2C9TSHR
SCHEMBL25214463 0.74 OPRD1 (0.41) GPR119POLBSMN1; SMN2
SCHEMBL22325282 0.73 SMN1; SMN2 (0.40) ALDH1A1TSHRBCHEL3MBTL1POLB
SCHEMBL720547 0.71 CHRM2 (0.49) GPR119KMT2A
SCHEMBL989650 0.67 SLC6A3 (0.50) KMT2ACYP1A2CYP2D6TSHRCYP2C19
SCHEMBL989948 0.67 SLC6A3 (0.50) KMT2ACYP1A2CYP2D6TSHRCYP2C19
SCHEMBL26923262 0.66 LMNA (0.38) ALDH1A1KMT2ACYP1A2CYP2D6CYP2C9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230054781-A1 METHODS AND COMPOSITIONS FOR MODULATING SPLICING SKYHAWK THERAPEUTICS, INC. 2023-02-23 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230054781-A1 METHODS AND COMPOSITIONS FOR MODULATING SPLICING RBM17, SF3B1, SF3B5 GPR119 4029/4885ALDH1A1 3964/4885KMT2A 2420/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback